Skip to main content
Top

26-10-2023 | Prostate Cancer | News

ESMO 2023

Added value for combination radium-223 and enzalutamide in mCRPC

MedNet.nl: In the REASSURE study, a combination treatment consisting of radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer (mCRPC). A phase 3 trial, the PEACE III trial, is now underway investigating the combination in a randomized setting.

Related topics

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine